VCANBIO(SH:600645) 智通财经网·2025-08-04 07:48Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received the acceptance notice for the clinical trial application of VUM02 injection from the National Medical Products Administration (NMPA) on August 1, 2025, marking a significant step in the development of a new treatment for post-pneumonia pulmonary fibrosis [1] Group 1 - VUM02 injection is an autologous cryopreserved cell preparation derived from selected healthy newborn umbilical cord tissue, aimed at treating post-pneumonia pulmonary fibrosis [1] - There are currently no similar cell drugs approved globally for the treatment of post-pneumonia pulmonary fibrosis, with the fastest progressing similar drugs still in early research stages [1] - The application for this indication is supported by previous clinical research data from COVID-19 and idiopathic pulmonary fibrosis Phase I clinical trials [1]